ZEVRA THERAPEUTICS INC (ZVRA)
US4884452065 - Common Stock
We assign a fundamental rating of 3 out of 10 to ZVRA. ZVRA was compared to 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ZVRA have multiple concerns. ZVRA shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
ZVRA had negative earnings in the past year.
ZVRA had a negative operating cash flow in the past year.
ZVRA had negative earnings in each of the past 5 years.
ZVRA had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
ZVRA's Return On Assets of -44.34% is in line compared to the rest of the industry. ZVRA outperforms 42.41% of its industry peers.
The Return On Equity of ZVRA (-121.72%) is worse than 62.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.34% | ||
| ROE | -121.72% | ||
| ROIC | N/A |
ROA(3y)-36.67%
ROA(5y)-91.49%
ROE(3y)-57.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of ZVRA (53.72%) is better than 63.35% of its industry peers.
ZVRA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 53.72% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ZVRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ZVRA has been increased compared to 1 year ago.
The number of shares outstanding for ZVRA has been increased compared to 5 years ago.
ZVRA has a worse debt/assets ratio than last year.
2.2 Solvency
ZVRA has an Altman-Z score of -2.14. This is a bad value and indicates that ZVRA is not financially healthy and even has some risk of bankruptcy.
ZVRA's Altman-Z score of -2.14 is in line compared to the rest of the industry. ZVRA outperforms 43.98% of its industry peers.
A Debt/Equity ratio of 0.84 indicates that ZVRA is somewhat dependend on debt financing.
ZVRA has a worse Debt to Equity ratio (0.84) than 70.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.84 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.14 |
ROIC/WACCN/A
WACC9.32%
2.3 Liquidity
A Current Ratio of 2.88 indicates that ZVRA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.88, ZVRA is in line with its industry, outperforming 49.21% of the companies in the same industry.
ZVRA has a Quick Ratio of 2.88. This indicates that ZVRA is financially healthy and has no problem in meeting its short term obligations.
ZVRA has a Quick ratio (2.88) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.88 | ||
| Quick Ratio | 2.88 |
3. Growth
3.1 Past
ZVRA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -71.30%.
The Revenue has grown by 49.58% in the past year. This is a very strong growth!
ZVRA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 27.37% yearly.
EPS 1Y (TTM)-71.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-72.5%
Revenue 1Y (TTM)49.58%
Revenue growth 3Y27.37%
Revenue growth 5YN/A
Sales Q2Q%27.63%
3.2 Future
ZVRA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.14% yearly.
Based on estimates for the next years, ZVRA will show a very strong growth in Revenue. The Revenue will grow by 67.66% on average per year.
EPS Next Y-51.8%
EPS Next 2Y28.74%
EPS Next 3Y35.28%
EPS Next 5Y34.14%
Revenue Next Year-21.53%
Revenue Next 2Y93.39%
Revenue Next 3Y87.49%
Revenue Next 5Y67.66%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
ZVRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZVRA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ZVRA's earnings are expected to grow with 35.28% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.74%
EPS Next 3Y35.28%
5. Dividend
5.1 Amount
ZVRA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ZEVRA THERAPEUTICS INC
NASDAQ:ZVRA (12/20/2024, 8:00:02 PM)
After market: 8.72 +0.23 (+2.71%)8.49
-0.05 (-0.59%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners0.23%
Ins Owner Change18.6%
Market Cap453.20M
Analysts84.29
Price Target21.42 (152.3%)
Short Float %8.64%
Short Ratio6.94
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-34.51%
Min EPS beat(2)-60.59%
Max EPS beat(2)-8.43%
EPS beat(4)1
Avg EPS beat(4)-24.3%
Min EPS beat(4)-60.59%
Max EPS beat(4)17.96%
EPS beat(8)2
Avg EPS beat(8)-20.29%
EPS beat(12)3
Avg EPS beat(12)-21.21%
EPS beat(16)4
Avg EPS beat(16)-31.48%
Revenue beat(2)1
Avg Revenue beat(2)-12.73%
Min Revenue beat(2)-25.59%
Max Revenue beat(2)0.14%
Revenue beat(4)2
Avg Revenue beat(4)-6.46%
Min Revenue beat(4)-25.59%
Max Revenue beat(4)10.39%
Revenue beat(8)4
Avg Revenue beat(8)13.66%
Revenue beat(12)6
Avg Revenue beat(12)9.01%
Revenue beat(16)8
Avg Revenue beat(16)35.98%
PT rev (1m)-1.56%
PT rev (3m)6.33%
EPS NQ rev (1m)-94.28%
EPS NQ rev (3m)-94.28%
EPS NY rev (1m)-14.86%
EPS NY rev (3m)-19.8%
Revenue NQ rev (1m)-44.36%
Revenue NQ rev (3m)-44.36%
Revenue NY rev (1m)-12.92%
Revenue NY rev (3m)-23.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 18.28 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 6.5 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.97
EYN/A
EPS(NY)-0.44
Fwd EYN/A
FCF(TTM)-1.3
FCFYN/A
OCF(TTM)-1.3
OCFYN/A
SpS0.46
BVpS1.31
TBVpS-0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.34% | ||
| ROE | -121.72% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 53.72% | ||
| FCFM | N/A |
ROA(3y)-36.67%
ROA(5y)-91.49%
ROE(3y)-57.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.84 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 1.38% | ||
| Cap/Sales | 0.31% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.88 | ||
| Quick Ratio | 2.88 | ||
| Altman-Z | -2.14 |
F-Score2
WACC9.32%
ROIC/WACCN/A
Cap/Depr(3y)25.82%
Cap/Depr(5y)19.71%
Cap/Sales(3y)0.76%
Cap/Sales(5y)0.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-71.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-72.5%
EPS Next Y-51.8%
EPS Next 2Y28.74%
EPS Next 3Y35.28%
EPS Next 5Y34.14%
Revenue 1Y (TTM)49.58%
Revenue growth 3Y27.37%
Revenue growth 5YN/A
Sales Q2Q%27.63%
Revenue Next Year-21.53%
Revenue Next 2Y93.39%
Revenue Next 3Y87.49%
Revenue Next 5Y67.66%
EBIT growth 1Y-103.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-65.01%
EBIT Next 3Y37.49%
EBIT Next 5Y49.32%
FCF growth 1Y-358.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-360.42%
OCF growth 3YN/A
OCF growth 5YN/A